secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jaguar Health, Inc. (JAGX)
CIK:        0001585608
Form:       8-K
Filed at:   2025-08-19T23:59:59+00:00
Accession:  0001193125-25-183449
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jaguar Health: Crofelemer cuts TPN needs in MVID/SBS; FDA outlines sNDA path for breast cancer
--------------------------------------------------------------------------------

- All 7 proposals approved at Aug 19 annual meeting; directors elected, stock plan amended, share issuances authorized.
- Initial proof-of-concept data: crofelemer reduced TPN up to 27% in MVID patient and up to 12.5% in SBS-IF patient.
- FDA meeting aligned on regulatory pathway to complete supplemental NDA for crofelemer in metastatic breast cancer (orphan population).
- Company plans to seek license partnerships for orphan indications to generate non-dilutive funding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1585608/000119312525183449/0001193125-25-183449-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1585608/000119312525183449/d947561d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-183449

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer